![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 14, 2019 6:11:36 AM
Total Monthly NORMALIZED Retail ONLY Data April-2019
Amazing Numbers – ATH Across the Board in Numbers & market Share
V
TRx: 243,499 {vs 229,970; +5.88%} – Sector +1.54% -- ATH (29,219,892 vs 27,596,430)
NRx: 119,622 {vs 117,214; +2.05%} – Sector -1.04% -- ATH (14,354,580 vs 14,065,633)
Ref: 123,878 {vs 112,757; +9.86%} – Sector +4.09% -- ATH (14,865,312 vs 13,530,797)
Gen L
TRx: 263,223 {vs 268,647; -2.02%} (31,586,768 vs 32,237,620)
NRx: 126,149 {vs 130,917; -3.64%} (15,137,851 vs 15,710,065)
L
TRx: 5,658 {vs 5,979; -5.36%} (679,000 vs 717,420)
NRx: 2,231 {vs 2,484; -10.18%} (267,767 vs 298,121)
Monthly NORMALIZED Retail TRx Market Share: 47.52% vs 45.58% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 48.23% vs 46.77 % --- ATH
Monthly NORMALIZED Retail Refills Market Share: 46.86% vs 44.40% --- ATH
April-2019 vs. April-2018 (NORMALIZED Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board, way better than non-normalized data; ~75% increase in TRx & ~90% increase in NRx
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+16% TRx & ~+23% NRx) and at the same time increasing its own Market Share
V
TRx: 243,499 {vs 138,578; +75.71%} – Sector +16.06% -- ATH (29,219,892 vs 16,629,379)
NRx: 119,622 {vs 63,539; +88.27%} – Sector +23.16% -- ATH (14,354,580 vs 7,624,711)
Ref: 123,878 {vs 75,039; +65.08%} – Sector +10.10% -- ATH (14,865,312 vs 9,004,668)
Gen L
TRx: 263,223 {vs 268,044; -1.80%} (31,586,768 vs 32,165,279)
NRx: 126,149 {vs 121,894; +3.49%} (15,137,851 vs 14,627,293)
L
TRx: 5,658 {vs 34,859; -83.77%} (679,000 vs 4,183,098)
NRx: 2,231 {vs 15,931; -86.00%} (267,767 vs 1,911,747)
V Apr-2019 NORMALIZED Retail ONLY TRx Market Share: 47.52% vs 31.39% in Apr-2018 --- ATH
V Apr-2019 NORMALIZED Retail ONLY NRx Market Share: 48.23% vs 31.55% in Apr-2018 --- ATH
V Apr-2019 NORMALIZED Retail ONLY Ref Market Share: 46.86% vs 31.25% in Apr-2018 --- ATH
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM